SS
NRIX icon

SBI Securities’s Nurix Therapeutics NRIX Stock Holding History

SBI Securities’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403 Sell
26
-150
-85% -$2.49K ﹤0.01% 2971
2025
Q4 		$3.34K Buy
176
+143
+433% +$2.05K ﹤0.01% 2194
2025
Q3 		$305 Buy
33
+15
+83% +$156 ﹤0.01% 3178
2025
Q2 		$205 Buy
+18
New +$195 ﹤0.01% 3295

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

SBI Securities's NRIX Position: Q1 2026 in Review

SBI Securities reduced its Nurix Therapeutics (NRIX) stake by 85% in Q1 2026, selling an estimated $2.49K and leaving 26 shares worth $403. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

SBI Securities first reported a position in NRIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.34K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • SBI Securities held 26 shares of Nurix Therapeutics worth $403 as of Q1 2026.
  • SBI Securities sold 150 Nurix Therapeutics shares in Q1 2026, an estimated $2.49K.
  • Nurix Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2971 holding.
  • SBI Securities first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • SBI Securities's Nurix Therapeutics position peaked at $3.34K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.